ClinicalTrials.gg
CompletedNCT05763082Updated Aug 26, 2026Results posted

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

A Phase 3 interventional study of roflumilast cream 0.3% and Zoryve in Plaque Psoriasis, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
3rd of 17
416 · median 46
Started
2023
with 1 other
Phase 3
5 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
1 of 17
Padagis LLC

Among the 17 studies testing roflumilast in Psoriasis, this one is the 3rd largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 13th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed IRB approved written /assent
  2. 12 to 75 years of age, inclusive.
  3. Subjects must have a clinical diagnosis of stable symptomatic plaque psoriasis.
  4. Baseline Investigator's Global Assessment Score of 3 (moderate).
  5. Subjects must have a Body Surface Area (BSA) between 2% to 20%
  6. Females of child bearing potential (excluding women who are surgically sterilized (tubal ligation or bilateral oophorectomy or hysterectomy) or for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day1(Baseline), must be willing to use an acceptable form of during the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, breastfeeding or planning a pregnancy within the period of their study participation period.
  2. Current diagnosis of unstable forms of psoriasis in the treatment area.
  3. History of unresponsiveness to topical treatment for psoriasis
  4. Presence of any other skin condition that, in the Investigator's opinion, might interfere with psoriasis diagnosis and/or evaluations
  5. Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments
  6. Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study
  7. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
  8. Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
416 participants (actual)

Study arms

  • Experimental
    Padagis active product

    Drug: roflumilast cream 0.3%

  • Active comparator
    Reference product

    Drug: Zoryve

  • Placebo comparator
    Padagis placebo product

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator's Global Assessment (IGA)

    percentage of subjects at Day 56 who achieve Treatment Success, which is defined as an IGA score of None (0) or Minimal (1) with a 2-grade improvement from Day 1

    Time frame: Day 1 to Day 56

07

Results

Posted Aug 26, 2026

Participant flow

Participant flow — Overall Study
MilestonePadagis Active ProductReference ProductPadagis Placebo Product
Started16916681
Completed15415575
Not completed15116

Outcome measures

PrimaryInvestigator's Global Assessment (IGA)

percentage of subjects at Day 56 who achieve Treatment Success, which is defined as an IGA score of None (0) or Minimal (1) with a 2-grade improvement from Day 1

Time frame:
Day 1 to Day 56
Reported as:
Count of participants · Participants
Investigator's Global Assessment (IGA)
ParticipantsPadagis Active ProductReference ProductPadagis Placebo Product
Investigator's Global Assessment (IGA)787922

Adverse events

Collected over Day 1 to 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Padagis Active Product0/169 (0%)0/169 (0%)0/169 (0%)
Reference Product0/166 (0%)0/166 (0%)0/166 (0%)
Padagis Placebo Product0/81 (0%)0/81 (0%)0/81 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Padagis Active ProductReference ProductPadagis Placebo ProductTotal
Mean50.3 ± 13.849.0 ± 13.948.8 ± 13.249.3 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Padagis Active ProductReference ProductPadagis Placebo ProductTotal
Female776634177
Male9210047239
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Padagis Active ProductReference ProductPadagis Placebo ProductTotal
American Indian or Alaska Native0202
Asian53210
Native Hawaiian or Other Pacific Islander1102
Black or African American32321478
White12912361313
More than one race1113
Unknown or Not Reported1438
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Padagis Active ProductReference ProductPadagis Placebo ProductTotal
Hispanic or Latino989850246
Not Hispanic or Latino716831170
Unknown or Not Reported0000
08

Study locations

1 site
  • DS Research
    Louisville, Kentucky 40241, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Aug 2023, 6 months.

Results were first posted in Aug 2026, 3 years after primary completion. A results delay was requested in Aug 2024.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 6 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 10, 2023
StartActual
Feb 7, 2023
Primary completionActual
Aug 8, 2023
CompletionActual
Aug 8, 2023
Results delay requested
Aug 7, 2024
Results first posted
Aug 26, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05763082
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Feb 7, 2023
Primary completion
Aug 8, 2023
Completion
Aug 8, 2023
Results posted
Aug 26, 2026
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion